Aprea Therapeutics, Inc. (APRE) Stock Price & Analysis
Aprea Therapeutics, Inc. (APRE) rose 0.16% to USD 0.63 as of July 25, 2026 at 04:53 UTC, according to Nexqual real-time market data.
APRE last closed at USD 0.63; the session ranged USD 0.61–0.7 on volume of 15,060 shares. Market capitalization is $7.83M, with a 52-week range of USD 0.55–2 (NCM). Source: Nexqual, July 25, 2026 at 04:53 UTC.
Key Statistics (as of July 25, 2026 at 04:53 UTC)
| Price | USD 0.63 |
|---|---|
| Change | ▲ 0.16% (up) |
| Previous Close | USD 0.63 |
| Open | USD 0.7 |
| Day Range | USD 0.61 – 0.7 |
| 52-Week Range | USD 0.55 – 2 |
| Volume | 15,060 shares |
| Market Cap | $7.83M |
| Exchange | NCM |
Technical Analysis (APRE)
Nexqual's technical model rates APRE "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 04:53 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 36.23 (neutral) |
| vs SMA50 | Below (USD 0.78) |
| MACD | -0.04 (negative) |
Analyst Ratings (APRE)
Wall Street analysts rate APRE "None" based on 4 analysts, with a mean price target of USD 4.3 (range USD 1.2–6), per Nexqual as of July 25, 2026 at 04:53 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 4.3 |
| High Target | USD 6 |
| Low Target | USD 1.2 |
| Buy / Hold / Sell | 4 / 0 / 0 |
Earnings (APRE)
| EPS Estimate | USD -0.22 |
|---|---|
| Revenue Estimate | $126,500 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.22 vs est -0.23 ▲ beat |
| 2025-12-31 | USD -0.32 vs est -0.36 ▲ beat |
| 2025-09-30 | USD -0.47 vs est -0.1 ▼ miss |
| 2025-06-30 | USD -0.53 vs est -0.71 ▲ beat |
Source: Nexqual, July 25, 2026 at 04:53 UTC.
Financials & Fundamentals (APRE)
| Total Revenue | $123,296 |
|---|---|
| Gross Margin | +0.00% |
| Operating Margin | -10202.01% |
| Profit Margin | +0.00% |
| ROE | -40.40% |
| Current Ratio | 8.92 |
| Total Cash | $46.47M |
| Total Debt | $0 |
| Free Cash Flow | $-5.63M |
Source: Nexqual, July 25, 2026 at 04:53 UTC.
Financial Health Score (APRE)
Nexqual rates Aprea Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 04:53 UTC.
| Growth | Critical — Revenue -81% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $46M cash, no debt |
| Cash Flow | Weak — FCF negative: -$6M, burning cash |
| Efficiency | Critical — ROE -40%, ROA -23.2% |
Ownership (APRE)
| Insider Ownership | +13.46% |
|---|---|
| Institutional Ownership | +18.13% |
| Shares Outstanding | 12.38M |
| Float | 7.41M |
| Short % of Float | +0.52% |
Source: Nexqual, July 25, 2026 at 04:53 UTC.
Leadership (APRE)
Aprea Therapeutics, Inc. is led by Oren Gilad (age 57), Co-Founder, CEO, President & Director, per Nexqual as of July 25, 2026 at 04:53 UTC.
| Co-Founder, CEO, President & Director | Oren Gilad (age 57) |
|---|---|
| Senior VP, CFO, Principal Accounting Officer & Secretary | John P. Hamill (age 61) |
| Senior VP & Chief Scientific Officer | Lars B. Abrahmsen (age 68) |
| Senior Vice President of Corporate Development & Strategy | Brian Wiley (age 57) |
Major Backers & Investors (APRE)
Notable institutional backers of Aprea Therapeutics, Inc. include AIGH Capital Management LLC, Vestal Point Capital, LP, Sphera Funds Management Ltd., according to Nexqual as of July 25, 2026 at 04:53 UTC.
Active Investors
| Investor | Stake |
|---|---|
| AIGH Capital Management LLC | 8.2% |
| Vestal Point Capital, LP | 2.83% |
| Sphera Funds Management Ltd. | 2.18% |
| Nantahala Capital Management, LLC | 1.66% |
| Fidelity | 0.78% |
| Scientech Research LLC | 0.49% |
| BNP Paribas Financial Markets | 0.32% |
| Renaissance Technologies | 0.2% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Geode Capital | 0.96% |
| Vanguard Group | 0.47% |
Source: Nexqual, July 25, 2026 at 04:53 UTC.
From Aprea Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-16)
Key Strengths & Strategy (as disclosed to the SEC)
- Although we take steps to protect our proprietary information and trade secrets, including through contractual means with our employees and consultants, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose our technology.
- If it becomes necessary for us to use patented or proprietary technology of third parties to develop or commercialize our product candidates, we may need to seek a license from such third parties.
- Our approach focuses on matching treatments to specific cancer-related genetic mutations to potentially maximize effectiveness and minimize side effects.
- Our approach is to inhibit these make up genes, thereby specifically killing cancer cells with defined mutations.
Partnerships
- APR-1051 Exhibits Strong Tumor Control in CCNE1-Overexpressing CDX Model In addition, pre-clinical results from an ongoing translational research collaboration with renowned oncology leader MD Anderson Cancer Center support the potential of APR-1051 both as a single agent and in rational immunotherapy combinations in HPV+ head and neck squamous cell carcinoma (HNSCC).
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ASMB | Assembly Biosciences, Inc. | USD 25.55 | ▼ 1.88% |
| GRTXD | Galera Therapeutics, Inc. | USD 17.5 | ▲ 7.64% |
| CYCN | Cyclerion Therapeutics, Inc. | USD 3.5 | ▼ 3.58% |
| ATXI | Avenue Therapeutics, Inc. | USD 0.28 | ▲ 2.22% |
| BYSI | BeyondSpring, Inc. | USD 1.12 | ▼ 0.88% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 04:53 UTC. This page is informational and not investment advice.